MIRA INFORM REPORT

 

 

Report No. :

334852

Report Date :

06.08.2015

 

IDENTIFICATION DETAILS

 

Name :

SOLUCIONES EN INNOVACION FARMACEUTICA SAS

 

 

Registered Office :

Carrera 50 # 50 - 14 Piso 15 Oficina 01, Edificio Banco Popular Medellin

 

 

Country :

Colombia

 

 

Date of Incorporation :

2000

 

 

Legal Form :

Sociedad Anónima Simplificada

 

 

Line of Business :

·         Provide General Pharmaceutical Raw Materials and Manufactured Products.

·         The subject has different categories for their products:

Pellets, Veterinary, Direct Compression and API´s.

 

 

No. of Employees :

11

 

 

RATING & COMMENTS

 

MIRA’s Rating :

B

 

RATING

STATUS

PROPOSED CREDIT LINE

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

Small

 

 

Status :

Small Company

Payment Behaviour :

No Complaints

Litigation :

Clear

 

NOTES:

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

 

ECGC Country Risk Classification List – March 31, 2015

 

Country Name

Previous Rating

(31.12.2014)

Current Rating

(31.03.2015)

Colombia

B2

B2

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

COLOMBIA - ECONOMIC OVERVIEW

 

Colombia's consistently sound economic policies and aggressive promotion of free trade agreements in recent years have bolstered its ability to weather external shocks. Real GDP has grown more than 4% per year for the past four years, continuing almost a decade of strong economic performance. All three major ratings agencies have upgraded Colombia's government debt to investment grade, which helped to attract record levels of investment in 2013 and 2014, mostly in the hydrocarbons sector. Colombia depends heavily on energy and mining exports, making it vulnerable to a drop in commodity prices. Colombia is the world's fourth largest coal exporter and Latin America's fourth largest oil producer. Economic development is stymied by inadequate infrastructure, inequality, poverty, narco-trafficking and an uncertain security situation. Moreover, the unemployment rate of 9.2% in 2014 is still one of Latin America's highest. The SANTOS Administration's foreign policy has focused on bolstering Colombia's commercial ties and boosting investment at home. Colombia has signed or is negotiating Free Trade Agreements (FTA) with more than a dozen countries; the US-Colombia FTA went into force on May 2012. Colombia is also a founding member of the Pacific Alliance - a regional grouping formed in 2012 by Chile, Colombia, Mexico, and Peru to promote regional trade and economic integration. In 2013, Colombia began its ascension process to the OECD. In 2014, Colombia passed a tax reform bill to offset the lost revenue from the global drop in oil prices. The SANTOS administration is also using tax reform to help finance implementation of a peace deal, in the event FARC and the government reach an agreement in 2015. Colombian officials estimate a peace deal may bolster economic growth by almost 2%.

 

Source : CIA

REGISTERED NAME & COMPANY SUMMARY

 

IDENTIFICATION

Ordered as:

SOLUCIONES EN INNOVACION FARMACEUTICA SAS

 

Address in the order:

CARRERA 50 # 50 - 14 PISO 15 OFICINA 01, EDIFICIO BANCO POPULAR MEDELLIN – COLOMBIA

 

Legal Name:

SOLUCIONES EN INNOVACION FARMACEUTICA S.A.S.

Trade Name:

Gate Pharma

Legal Address

CARRERA 50 # 50 - 14 PISO 15 OFICINA 01, EDIFICIO BANCO POPULAR

Postal Town

MEDELLIN

Post Code

N.A

Primary Geographic Area

Antioquia

Country

CO

Operative Address

CARRERA 50 # 50 - 14 PISO 15 OFICINA 01, EDIFICIO BANCO POPULAR, MEDELLIN, Antioquia, COLOMBIA

Telephone:

+57 4 444 0082

NIT :

900697636-1

Fax:

+57 4 444 0082

Legal Form:

Sociedad Anónima Simplificada

Email:

mercadeo@gatepharma.com.co

Registered in:

CO

Website:

http://gatepharma.com.co

Date Created:

2000

MANAGERS:

Mr. Felipe Velez Roa, General Manager

Date Incorporated:

N.A

Staff:

11

Stock:

N.A

 

 

Value:

N.A

Activity:

Provide general pharmaceutical raw materials and manufactured products.

 

 

DIRECTORS/MANAGEMENT

 

Management:

 

Mr. Felipe Velez Roa, General Manager and Legal Representative.

 

Mrs. Sandra Julieth Herrera Restrepo, Commercial Director.

 

 

NEGATIVE INFORMATION

 

 

Legal Filings

 The sources consulted record no detrimental legal or labor court information.

 

 

SHARE & SHARE CAPITAL INFORMATION

 

Shareholders - RELATED COMPANIES

Listed at the stock exchange:

 

NO

Shareholders Parent Company(ies):

 

The subject is a private company. The main shareholder is Felipe Velez Roa.

 

 

PAYMENT INFORMATION

 

Clients:

 

Pharmaceutical industry.

Suppliers:

 

We could not find suppliers for the subject.

 

The company imports from China and India

The company does not export

Trade References:

 

We could not find trade references for the subject.

 


DEBT COLLECTIONS AND PAYMENTS

Public

NO

Payments

REGULAR

 

 

GROUP STRUCTURE & AFFILIATED COMPANIES

 

N/a

 

 

FINANCIAL INFORMATION

 

FINANCIALS - COMMERCIAL TRENDS AND FORECAST

As a private company the subject does not publish any financial statements.

We have contacted Natalia Bustamante from the Sale and Logistic Department who refused to provide us any financial data on grounds of confidentiality.

 


FINANCIAL SUMMARY

Profitability

N.A.

Indebtedness

CONTROLLED

Cash

NORMAL

 

 

FOREIGN EXCHANGE RATES

 

N/a

 

 

ADDITIONAL INFORMATION

 

GEOPOLITICS - COLOMBIA

POLITICAL DATA

ECONOMIC DATA

Form of Government: Republic


Economic Risk: Low

Currency: 100,00 COP = 0,0344237 USD

Branch Situation: Stable

 

BANKS

 

Name of the Bank

BANCOLOMBIA

Comments

This information was verified by the company.

 

BUSINESS HISTORY

 

 

SOLUCIONES EN INNOVACIÓN FARMACÉUTICA S.A.S. was established in 2000 in Colombia.

 

The subject is ISO 9001:2008 certified.

PRINCIPAL ACTIVITY

 

Provide general pharmaceutical raw materials and manufactured products.

 

Products/Services description:

 

The subject has different categories for their products:

 

Pellets, veterinary, direct compression and API´s.

 

 

Sales are:

 

Wholesale

 

Brands:

 

The subject does not present brands.

 

Operations area:

 

National, Local

 

The subject employs 11 employee(s)

Comments on staff:

 

This information was verified by the company.

 

LOCATION

 

Headquarters

 

CARRERA 50 # 50 - 14 PISO 15 OFICINA 01, EDIFICIO BANCO POPULAR, MEDELLIN, Antioquia, COLOMBIA

Branches:

 

The subject does not present branch locations.

 

 

NOTES & COMMENTS

 

 

 Final Opinion

 

SOLUCIONES EN INNOVACIÓN FARMACÉUTICA S.A.S. was established in 2000 in Colombia.

 

The subject is a small size private company that provides general pharmaceutical raw materials and manufactured products. It is commonly known as Gate Pharma.

 

The subject imports mainly from India and China and they don´t export, they only distribute them in their local market.

 

During the investigation no late payments or legal actions were found against the subject.

 

 

APPENDIX

 

Person Interviewed

 

Natalia Bustamante

Position

 

Representative of Sale and Logistic Department

Comments

 

She provided us the following information:

 

Legal name and NIT

 

Branches

 

Headquarter

 

Sales Type

 

Employees

 

Manager

 

Commercial Activity

 

Bank

 

Trade Name

 

FOREIGN EXCHANGE RATES

 

Currency
Unit

Indian Rupees

US Dollar

1

Rs.63.82

UK Pound

1

Rs.99.15

Euro

1

Rs.69.31

 

 

INFORMATION DETAILS

 

Analysis Done by :

KAS

 

 

Report Prepared by :

TPT

 

               

RATING EXPLANATIONS

 

RATING

STATUS

PROPOSED CREDIT LINE

 

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

 

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

 

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

 

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

 

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

 

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

 

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

Credit not recommended

 

--

NB

New Business

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.